Latest in News & Research
Black Children Have Low Proportion of Dermatology Use
Findings seen for children with atopic dermatitis, acne, infantile hemangioma, psoriasis, and hidradenitis suppurativa
Dermoscopic Patterns of iSCC Vary by Anatomic Location, NCCN Risk
Linear irregular or arborizing vessels and ulceration were more often seen on high-risk tumors
AAD: Many Continue to Believe Tanning Myths, Seek Skincare Advice on Social Media
American Academy of Dermatology survey reveals one-third of U.S. adults reported past-year sunburn
FDA Approves Dupixent for Chronic Spontaneous Urticaria in Young Children
The expanded indication is for children ages 2 to 11 years who remain symptomatic despite histamine-1 antihistamine treatment
Adverse Events Not Increased With Multiple ITIs in Hidradenitis Suppurativa
Short- or long-term risk for adverse corticosteroid effects did not increase with multiple intramuscular triamcinolone injections
Model Provides Well-Calibrated Risk Estimates for First Metachronous cSCC
Discrimination modest, but model demonstrated excellent calibration across predictor subgroups
Predictive Model Shows Moderate Performance for Psoriasis Relapse Risk
BMI, diabetes, biologic use, smoking, URTI, nonstandard medication were identified as independent risk factors and included in model
Atopic Dermatitis Linked to Sleep, Memory Disturbances
Higher risk seen with increasing disease severity
Machine Learning Predicts Asthma Risk in Children With Early-Life Atopic Dermatitis
Models built based on routine electronic health record data
The Long View of Atopic Dermatitis Control
In treating atopic dermatitis, the question is not only how quickly a patient can improve, but how to build a plan that respects the...
News Alert: Phase 3 ONWARD Trials Evaluate Envudeucitinib in Moderate to Severe Plaque Psoriasis
Findings presented at AAD26 highlight rapid onset and deepening responses through week 24
A Shift in Access for Actinic Keratosis
A late-March formulary update may change how often tirbanibulin is a realistic option in clinic.
Maternal Prepregnancy BMI, Birth Length Linked to Offspring Atopic Dermatitis
Increasing birth length positively associated with atopic dermatitis by age 3 years, while inverse association seen for short birth length
American Academy of Dermatology, March 27 to 31
The annual meeting of the American Academy of Dermatology was held from March 27 to 31 in Denver and attracted clinicians, academicians, allied health...
Recommendations Developed for Prevention of Pediatric Atopic Dermatitis
Guidelines also developed for medical management of pediatric atopic dermatitis, including 27 evidence-based recommendations
Mortality Varies With Primary Tumor Location in Cutaneous Melanoma
Increased mortality seen with primary tumor location in head and neck site; mortality reduced for location in upper limb/shoulder and lower limb/hip
Consensus-Based Definitions Developed for Disease Activity in Atopic Dermatitis
Definitions developed for low disease activity, very low disease activity, remission in atopic dermatitis
News Alert: Deucravacitinib Approved for Psoriatic Arthritis
An oral TYK2 inhibitor now carries an indication across both skin and joint disease
What It Means to Treat Something That Doesn’t Behave Consistently
Atopic dermatitis rarely behaves the same way twice, which means the real work of treating it begins in everything we don’t immediately see.
Nailing Down a Diagnosis: When Dermatology Is Not Just Skin Deep
Sometimes the smallest structure in the exam, the nail, offers some of the clearest clues to what’s really going on beneath the surface.
International Severity Criteria Developed for Vitiligo
Major criteria for vitiligo include spread or active disease, involvement of highly visible or high-impact areas, psychological distress
AAD: Zasocitinib Safe, Effective for Moderate-to-Severe Plaque Psoriasis in Adults
Phase 3 studies show the highly selective oral tyrosine kinase 2 inhibitor provides rapid, durable skin improvement
AAD: Upadacitinib Safe, Effective for Nonsegmental Vitiligo
Benefits include total and facial repigmentation in patients 12 years and older versus placebo
24 of 1274